246.00
+1.32%
Close of 9 Nov 2026, in DKK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ALK-Abello A/S
Its shares trade on Nasdaq Copenhagen under the ticker ALK B.CO. It has been listed since 1 January 1961. In the fiscal year to 31 December 2025, it reported revenue of DKK 6.31bn and net income of DKK 1.20bn. At that date it held total assets of DKK 9.17bn and shareholders' equity of DKK 6.45bn.
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The company is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The firm operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jan 1961
- Employees
- 2,404
- Website
- alk.net ↗
Leadership
Pay as last reported
- Mr. Anders HedegaardIndependent Chairman of the BoardDKK 1.3m
- Mr. Peter HallingPresident, Chief Executive OfficerDKK 2.0m
- Ms. Lene Skole-SoerensenVice Chairman of the Board, since 2014DKK 900,000
- Mr. Claus SoljeExecutive Vice President, Chief Financial OfficerDKK 4.1m
- Mr. Christian HoughtonExecutive Vice President - Product Supply
- Dr. Henriette MersebachExecutive Vice President - Research and DevelopmentDKK 4.9m
- Mr. Soeren NiegelExecutive Vice President - Commercial OperationsDKK 6.5m
- Ms. Lika ThiesenExecutive Vice President - Global People and Organization
- Mr. Jacob GlentingSenior Vice President - Global Strategy and Corporate Development
- Mr. Jan Engel JensenSenior Vice President - Global Quality
- Ms. Katja BarnkobDirector, Employee RepresentativeDKK 350,000
- Ms. Nanna CarlsonDirector, Employee RepresentativeDKK 350,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 99
- Social
- 99
- Governance
- 45
- Direct emissions (scope 1)
- 5,128 t
- Energy emissions (scope 2)
- 5,917 t
- Value chain emissions (scope 3)
- 64,067 t
- Women in the workforce
- 62%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company produces allergy vaccines including tablet and sublingual options.
- Emergency treatments for anaphylaxis management are part of the portfolio.
- Allergy diagnostics include allergen extracts for skin-prick tests globally.
Weaknesses
- The firm operates through subsidiaries in many countries worldwide.
- Production units are distributed across multiple international locations.
- Distributors handle sales in countries like Austria and Canada.
Opportunities
- Expansion into China offers new market potential for products.
- The United States represents a significant opportunity for growth.
- Subsidiaries in France and Italy support regional development.
Threats
- Competition exists in the pharmaceuticals sector for allergy treatments.
- Regulatory changes in Switzerland may impact product distribution.
- Economic conditions in Poland could affect sales performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.